Journal
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
Volume 452, Issue 3, Pages 795-800Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2014.08.149
Keywords
Osteopontin; Osteoclast survival; Bone resorption; Osteoporosis
Categories
Funding
- Ministry of Science and Technology of China (973 projects) [2012CB917104]
- National Natural Science Foundation of China [81172853, 81201605]
- Ministry of Health of the China (Major drug discovery projects) [2012ZX09102301-002]
- Shanghai Municipal Commission of Health and Family Planning [XYQ2011040]
Ask authors/readers for more resources
Osteopontin (OPN) is abundant in mineralized tissues and has long been implicated in bone remodeling. However, the therapeutic effect of targeting OPN in bone loss diseases and the underlying molecular mechanism remain largely unknown. Here, we reported that anti-OPN mAb (230) could protect against ovariectomy-induced osteoporosis in mice, demonstrated by microcomputed tomography analysis and histopathology evaluation. In vitro assay showed that 230 mAb reduced osteoclasts (OCs)-mediated bone resorption through promotion of mature OC apoptosis. Thus, the study has important implications for understanding the role of OPN in OC bone resorption and survival, and OPN antagonists may have therapeutic potential for osteoporosis and other osteopenic diseases. (C) 2014 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available